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Focal Lysolecithin-Induced Demyelination of Peripheral
Afferents Results in Neuropathic Pain Behavior That Is
Attenuated by Cannabinoids
Victoria C. J. Wallace, David F. Cottrell, Peter J. Brophy, and Susan M. Fleetwood-Walker
Centre for Neuroscience Research, Division of Preclinical Veterinary Sciences, The Royal (Dick) School of Veterinary Studies, The University of Edinburgh,
Summerhall, Edinburgh EH9 1QH, United Kingdom
Demyelinating diseases can be associated with painful sensory phenomena such as tactile allodynia and hyperalgesia. To study the
mechanisms underlying demyelination-induced pain, we have characterized a novel model of demyelination of the sciatic or saphenous
nerve. Topical lysolecithin application causes focal demyelination of afferent nerve A-fibers without axonal loss, as assessed either by
electron and light microscopy or by immunohistochemical analysis of dorsal root ganglia (DRG) for a neuronal injury marker, activating
transcription factor 3. Focal demyelination is accompanied by spontaneous action potentials in afferents and increased expression of
neuropeptide Y and Nav1.3 sodium channels specifically in DRG neurons that coexpress a specific marker of myelinated afferents. In
contrast, expression of tetrodotoxin-resistant, Nav1.8 sodium channels is specifically decreased in the same subgroup of DRG cells.
Central sensitization of somatosensory processing is also induced, with increased behavioral reflex responsiveness to thermal and
mechanical stimuli. These changes are reversed by intrathecal administration of an NMDA receptor antagonist or cannabinoid (CB)
receptor agonist, but not by a-opioid receptor agonist. Recovery of behavioral reflexes occurred3 weeks after lysolecithin treatment.
This is the first time that demyelination of afferent A-fibers has been shown to specifically induce neuropathic pain and indicates that
axonal damage is not a prerequisite for development of the pain state. The profile of phenotypic changes in DRG is distinct from other pain
models and displays a sensitivity to NMDA and CB receptor agents that may be exploitable therapeutically.
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Introduction
Both the CNS and the peripheral nervous system (PNS) are suscep-
tible to demyelinating disorders in humans. In the PNS, Charcot-
Marie-Tooth disease types 1 and 4 (CMT1 and CMT4) and Guillain-
Barre´ syndrome (GBS) are accompanied not only by segmental
demyelination with reduced rates of nerve impulse transmission and
impaired motor function, but also by abnormal sensory phenomena
such as tactile allodynia (the perception of normally innocuous stim-
uli such as touching and brushing as painful), hyperalgesia (a height-
ened response to painful stimuli), and spontaneous pain (Carter et
al., 1998). However, the mechanisms underlying neuropathic pain
in demyelinating disease are poorly understood (Rasminsky, 1981).
Recently, we showed that mice lacking a functional Periaxin (Prx)
gene develop a late-onset peripheral demyelination, which is associ-
ated with reflex behaviors corresponding to allodynia and hyperal-
gesia (Gillespie et al., 2000). These enhanced sensory responses are
reversible by spinal administration of an NMDA receptor antago-
nist, implying a critical role for central sensitization in the pain be-
havior. Recently, mutations in the human PRX gene have been
shown to underlie CMT4. Consistent with the mouse model, there is
a particularly large sensory involvement in patients with CMT4F,
who display various distal abnormalities including pain in both up-
per and lower extremities (Delague et al., 2000; Boerkoel et al., 2001;
Guilbot et al., 2001; Takashima et al., 2002).
To determine how peripheral demyelination might contribute to
the development of the ensuing neuropathic pain state, we have
characterized a model of focal, reversible peripheral nerve demyeli-
nation of the sciatic or saphenous nerve using the selective demyeli-
nating agent lysolecithin (lysophosphatidyl choline) (Hall and Greg-
son, 1971). Using this model we have studied the effects of
demyelination on peripheral nerve function and on the phenotype
of cells in the dorsal root ganglia (DRG), including changes in the
expression of calcitonin gene-related peptide (CGRP), galanin, neu-
ropeptide Y (NPY), and the Nav1.8 (sensory neuron-specific type 1)
and Nav1.3 (brain type III) sodium channels. Furthermore, we have
investigated key changes in somatosensory processing within the
spinal cord. We show for the first time that transient demyelination
causes a distinctive profile of phenotypic changes in DRG. These
changes are accompanied by spontaneous activity in afferents and
central sensitization of sensory processing, all in the apparent ab-
sence of damage to the afferent axons. The sensitivity of the behav-
ioral reflex changes to NMDA receptor antagonists and cannabinoid
(CB) receptor agonists suggests therapeutic strategies for pain in-
duced by demyelination.
Materials and Methods
Animals and surgical methods. C57BL/6 mice over the age of 6 weeks were
used for all experiments. Animals were anesthetized with 0.3 ml 25%
Sagatal (Rhone Merieux, Hertfordshire, UK) in sterile physiological sa-
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line (intraperitoneal) and maintained on 1–2% halothane (Zeneca,
Cheshire, UK) in O2. For all demyelination experiments, lysolecithin
(Sigma, St. Louis, MO) was dissolved in physiological saline to give a final
concentration of 15 mg/ml.
Saphenous and sciatic nerve demyelination. The saphenous branch of
the femoral nerve was exposed at mid thigh level, and 5–10l lysolecithin
solution was applied topically via a 25 gauge needle (Terumo) over a
length of 5– 6 mm, ensuring that the nerve remained coated with the
solution for 10 min after which the reagent was washed off with sterile
saline and the incision site was closed with 4.0 suture thread, marking the
application site. For sciatic nerve demyelination experiments, once the
nerve was exposed at mid thigh level, the two larger fascicles (tibial and
peroneal) were separated by blunt dissection from the smallest sural
fascicle. Lysolecithin was applied to the tibial and peroneal fascicles for 15
min. Sham control animals were prepared for both nerve preparations by
omitting lysolecithin from the solution so that the nerve was exposed as
above and sterile saline was applied topically for the relevant time.
Behavioral reflex testing. The threshold for hindpaw withdrawal in re-
sponse to graded mechanical stimulation was measured in conscious
animals with von Frey filaments (Stoelting, Wood Dale, IL), which pro-
vide a calibrated indentation pressure against the hairless skin of the
hindpaws. The threshold response was defined by the filament that
caused foot withdrawal at least 5 times in every 10 applications (Meyer et
al., 1979; Chaplan et al., 1997). The time for hindpaw withdrawal in
response to a quantified noxious thermal stimulus was measured using
the Hargreaves-Plantar apparatus (Ugo Basile). The thermal stimulus
was of infrared intensity setting 30 (50°C) applied to the mid-plantar
surface of each hindpaw (Hargreaves et al., 1988). The withdrawal was
characterized as a brief paw flick, and the withdrawal latency was re-
corded in seconds.
Baseline measurements were obtained for all animals over the course of 1
week before surgery. Behavioral reflex tests were performed after surgery to
identify the development of any reflex sensitivity in treated animals. The
threshold value at each time point tested was calculated as the mean SEM.
Any statistically significant differences in paw withdrawal threshold from
mechanical stimulation between ipsilateral and contralateral paws were de-
termined by a Mann–Whitney rank sum test. Likewise, any statistically sig-
nificant differences in paw withdrawal latency from thermal stimulation
were determined by a Student’s paired t test.
Morphological investigations. Nerve morphology was examined in an-
imals that previously had focal demyelination induced in either the sa-
phenous or sciatic nerve. Sections of nerve from the region of lysolecithin
application were dissected 13 d later, fixed for 4 hr in 2.5% glutaralde-
hyde and 2% paraformaldehyde in 0.1 M sodium cacodylate buffer, pH
7.3, postfixed in OsO, and embedded in Araldite.
For light microscopy, 1 m resin sections of the demyelinated section of
the nerve (7–10 mm) were stained with Toluidine blue. Once the area of
maximal demyelination was established by bright-field microscopy, ultra-
thin (80 nm) sections were stained with uranyl acetate and lead citrate and
examined on a Phillips BioTwin electron microscope (FEI, UK Ltd.,
Cambridge, UK). Nerve counts were performed at the electron micro-
scope (EM) level so that the amount of demyelination and integrity of
large-diameter and small-diameter, unmyelinated axons could be deter-
mined. C-fibers were identified as small-diameter unmyelinated fibers
present in bundles, surrounded by Schwann cell cytoplasm. The number
of intact C-fibers was calculated from EM photographs of cross sections
of the entire nerve. To minimize error, the images from all nerves (n 4
per group) were randomly counted three times (while the source of each
image was concealed), and the average for each nerve was calculated. To
count the number of myelinated A-fibers, axons with all levels of myeli-
nation, including those that were completely demyelinated, must be con-
sidered. Therefore, A-fibers were identified as not only fibers with a
myelin sheath, but also solitary fibers with a smaller overall diameter
attributable to loss of myelin. This allowed distinction of demyelinated
fibers from unmyelinated fibers, which usually occur in bundles. The
statistical significance of any difference between treated and naive or
sham nerves was determined using a Kruskal–Wallis one-way ANOVA
on ranks with an all pair-wise multiple comparisons procedure (Dunn’s
method).
G-ratio. The g-ratio of an axon is a measure of myelin thickness calcu-
lated by dividing the axonal diameter by the total diameter of axon plus
myelin sheath. This gives an indication of the level of demyelination in
axons that are not completely demyelinated by lysolecithin treatment.
The g-ratios of myelinated fibers were calculated from EM photographs
of the whole cross-sectional area of each nerve using the IP Lab Spectrum
P program (Scanalytics, Fairfax, VA). This also calculates the number of
myelinated axons in the sample (292m 2) and enables the proportion of
completely demyelinated axons per nerve to be determined. The statisti-
cal significance of any difference among treated, naı¨ve, or sham nerves
was determined by Kruskal–Wallis one-way ANOVA on ranks with an all
pair-wise multiple comparisons procedure (Dunn’s method).
Electrophysiology. Electrophysiological recording of activity and func-
tion in afferent fiber units of peripheral nerve was performed on animals
that previously had focal demyelination induced in the saphenous nerve.
Recording experiments were performed on days 3 and 5 after surgery,
times at which behavioral reflex sensitization had not developed, and also
on days 11, 12, and 13 after surgery, corresponding to the peak time of
development of behavioral reflex sensitization.
Mice were anesthetized with 5% urethane (1.25 gm/kg, i.p.) and main-
tained at 36 –37°C with a radiant heat lamp. The saphenous nerve was
exposed in the mid thigh and dissected from its associated vein and
artery. Further dissection under liquid paraffin enabled the identification
of afferent preparations comprising a small number of units. The mech-
anosensitivity of sensory receptors with low thresholds was measured
using calibrated von Frey filaments, and the thermal threshold was mea-
sured with a calibrated radiant heat source. The mechanical threshold
was defined as the pressure required to cause units to fire in response to
direct application of von Frey filaments to the central zone of the identi-
fied receptive field, and the thermal threshold was defined as the temper-
ature required to cause units to fire in response to direct application of
the radiant heat source to the central zone of the identified receptive field.
The conduction velocity of single identified afferent fibers was deter-
mined using bipolar electrodes and the peripheral stimulus technique
(Iggo, 1958). The percentage of axons in each conduction velocity range,
from 0 –3 m/sec up to 18 –21 m/sec, was calculated, and the statistical
significance of any difference between each treatment group was deter-
mined by a Kruskal–Wallis one-way ANOVA on ranks with all pair-wise
multiple comparisons procedure (Dunn’s method). All recording traces
of spike activity were obtained via a direct link of the oscilloscope to the
Powerlab/MacLab Chart v3.6/s program (AD Instruments, Oxford, UK).
Data were subsequently analyzed on the Claris Works 4.0 illustrator
program (Claris Corporation, Smart Computing, Lincoln, NE).
Immunohistochemistry. For fixed-tissue immunohistochemistry, ani-
mals that 13 d previously had lysolecithin treatment of the right sciatic
nerve or saphenous nerve were deeply anesthetized with halothane and
perfused through the heart with heparinized saline followed by 4% para-
formaldehyde (Sigma) in 0.1 M phosphate buffer (Sigma). The DRG
ipsilateral and contralateral to the lysolecithin-treated nerve or sham-
operated nerve were removed, postfixed with the same fixative for 2 hr,
and transferred through increasing concentrations of sucrose in 0.1 M
phosphate buffer for 1 hr and left overnight in 25% sucrose in 0.1 M
phosphate buffer. The DRG were then embedded in OCT mounting
medium (Tissue Tek) and frozen over liquid nitrogen. For nonperfused
tissue immunohistochemistry, animals were killed by CO2 inhalation
13 d after lysolecithin treatment. DRG ipsilateral and contralateral to the
lysolecithin-treated nerve or sham-operated nerve were removed, snap
frozen, and embedded in OCT mounting medium. Cryostat sections of
all DRG (10 m) were thaw-mounted on glass slides precoated with
poly-L-lysine (Merck-BDH). For saphenous nerve-treated animals, L3,
L4, and L5 DRG were analyzed, and for sciatic-treated animals, L4, L5,
and L6 DRG were analyzed (all n 4).
For colocalization of Nav1.8 or the peptides CGRP or NPY with the
A-fiber cell body marker neurofilament 200 kDa (NF-200) (Lawson and
Waddell, 1991; Michael et al., 1999), or the C-fiber cell body marker
peripherin (Goldstein et al., 1991), nonperfused DRG sections were
immersion-fixed for 15 min in 4% paraformaldehyde in PBS. Sections
were preincubated in buffer (0.1 M PBS, pH 7.4, containing 0.2% Triton
X-100 and 2% gelatin) containing 10% normal goat serum or 10% nor-
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mal donkey serum (for CGRP detection) for 1 hr at room temperature
and incubated with primary antibodies diluted in buffer containing 4%
goat or donkey serum overnight at 4°C. Perfused tissue was used for
detecting colocalization of Nav1.3, galanin, or activating transcription
factor 3 (ATF3) (Tsujino et al., 2000) with NF-200 or peripherin. The
immunohistochemical procedure used was as for fresh tissue, omitting
the immersion-fixation step.
Antisera were used at the following concentrations: rabbit anti-Nav1.8
[1:200; K107 supplied by S. Tate, GlaxoSmithKline; specificity of K107
was tested by preincubating primary antibody with dilutions of the rele-
vant antigenic peptide (Amaya et al., 2000)]; rabbit anti-Nav1.3 sodium
channel [1:200; Alomone Labs, Jerusalem, Israel (Black et al., 1999)];
sheep anti-CGRP [1:1500; Affiniti, Exeter, UK (Todd, 1997)]; rabbit
anti-NPY [1:1000, Peninsula Laboratories, Belmont, CA (Polgar et al.,
1999)]; rabbit anti-galanin (1:2000; Advanced Chemtech, Cam-
bridgeshire, UK); rabbit anti-ATF3 (1:400; Santa Cruz Biotechnology,
Santa Cruz, CA); mouse monoclonal anti-NF-200 kDa [1:2000; clone
N52; Sigma (Bennett et al., 1998)]; and mouse monoclonal anti-
peripherin [1:1000; Chemicon International, Harlow, UK (Amaya et al.,
2000)]. Sections were then washed in buffer and incubated with the
appropriate secondary antibodies linked to either tetramethyl rhoda-
mine isothiocyanate (TRITC) (goat anti-mouse-TRITC, 1:200, to detect
all mouse primary antisera; Southern Biotechology, Birmingham, AL) or
fluorescein isothiocyanate (FITC) (goat anti-rabbit-FITC, 1:200, to de-
tect all goat primary antisera; Cappell; donkey anti-sheep-FITC, 1:100, to
detect anti-CGRP primary antiserum; Jackson ImmunoResearch Labo-
ratories, West Grove, PA) for 2 hr at room temperature. Three final
washes in 0.1 M PBS were conducted before coverslipping with Vecta-
Shield (Vector Laboratories, Burlingame, CA) for analysis. Control sec-
tions were processed as above omitting the primary antisera. Observa-
tions were made and sections were photographed on an Olympus
microscope equipped for epifluorescence. Counts of profiles labeled for
immunopositive cells were performed on four to five randomly selected
10m sections of DRG (separation of 100m) from each of four animals
in each group, and only neurons with clear nuclei were counted. Results
were expressed either as a proportion of labeled profiles per section or the
proportion per total number of single- or double-labeled profiles from all
16 –20 sections. The statistical significance between groups was tested by
Kruskal–Wallis one-way ANOVA on ranks with all pair-wise multiple
comparison procedures (Dunn’s method).
Intrathecal administration of drugs. Animals with focal demyelination in-
duced in the saphenous nerve were used for all intrathecal injection experi-
ments. Baseline measurements for mechanical allodynia and thermal hyper-
algesia were recorded over a period of up to 2 hr before injection. The mice
were briefly anesthetized with halothane and O2 and injected intrathecally at
the level of the L4 spinal vertebra using a 25 gauge needle with the NMDA
receptor antagonist 3-((R)-2-carboxypiperazine-4-yl)-propyl-1-phos-
phonic acid [(R)-CPP; Tocris Cookson, Bristol, UK; 100 pmol/10l saline],
the selective  opioid receptor agonist D-Ala2, MePhe4, Gly-ol enkephalin
(DAMGO; Tocris Cookson; 10 pmol/10 l saline), the mixed CB1/CB2
cannabinoid receptor agonist mesylate (R)-()-(2,3-dihydro-5-methyl-
3-(4-morpholinylmethyl) pyrrolo (1,2,3-de)-1,4-benzoxazin-6-yl)-1-naph-
thalenylmethanone [WIN 55,212–2; Tocris; 60 pmol/10 l saline with
0.02% dimethylformamide (DMF)], the selective CB1 receptor antagonist
N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,3-dichlorophenyl)-4-methyl-1H-
pyrazole-3-carboxamide (AM 251; Tocris; 100 pmol/10 l saline with
0.3% DMF), or a combination of WIN 55,212–2 plus AM 251 (100
pmol/10l saline with 0.3% DMF). To determine the effects of each drug
on both mechanical allodynia and thermal hyperalgesia, behavioral re-
flex testing commenced 15 min after injection to allow recovery from
anesthesia and continued every 5 min thereafter until readings returned
to baseline levels. For all drugs tested, any statistically significant differ-
Figure 1. Development of mechanical allodynia and thermal hyperalgesia ipsilateral to ly-
solecithin treatment of the saphenous or sciatic nerve. a, Filament indentation pressure thresh-
olds for paw withdrawal responses to von Frey filaments were measured after lysolecithin
treatment (1) to one saphenous (n  6) ( i) or one sciatic nerve (n  6) (ii). Statistical
significance of differences between ipsilateral () and contralateral () paws (*p 0.05)
was determined by a Wilcoxon test. Each value is the mean SEM. b, The time taken for
4
hindpaw withdrawal from a noxious thermal stimulus was measured after lysolecithin treat-
ment (1) to one saphenous (n 6) ( i) or one sciatic nerve (n 6) (ii). Statistical significance
between ipsilateral () and contralateral () paws (*p 0.05) was determined by a paired
Student’s t test. Each value is the mean SEM.
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ence of the postinjection paw withdrawal from baseline paw withdrawal
thresholds was determined by a one-way repeated measures ANOVA
with Dunnet’s multiple comparisons versus control group post hoc anal-
ysis. Extensive control studies have shown that intrathecal injections of
the vehicles, saline, or 0.1– 0.5% DMF in saline have no effect on these
behavioral reflex measures. Dye injections using Pontamine Sky Blue
demonstrated that over various time periods up to 60 min after injection
there was no spread of dye to the proximal spinal nerve or DRG.
Results
Lysolecithin treatment causes behavioral allodynia
and hyperalgesia
Lysolecithin-treated mice displayed a markedly lowered thresh-
old in reflex tests both of cutaneous mechanical sensitization
using calibrated von Frey filaments and of thermal nociceptive
sensitivity (Fig. 1). The heightened sensitivity to both tests was
apparent from day 5 after lysolecithin treatment of saphenous or
sciatic nerve, but reached peak values from day 9 until day 15 after
surgery. Typically, after lysolecithin treatment of the saphenous
nerve, von Frey thresholds were reduced from 700 to 300
mN/mm 2, and thermal withdrawal latencies were reduced from
9 to 5 sec at peak behavioral change. Similarly, after lysolecithin
treatment of the sciatic nerve, von Frey thresholds were reduced
from600 to250 mN/mm 2, and thermal withdrawal latencies
were reduced from 11 to 5 sec at peak behavioral change. In
each case the changes recovered to baseline levels by 23 d after
treatment. There was no evidence for overt motor deficit after
lysolecithin treatment of either nerve. Furthermore, mice that
had undergone surgery and saline treatment of the saphenous or
sciatic nerve showed no change from baseline von Frey threshold
withdrawal values of between 600 and 700 mN/mm 2 or baseline
thermal paw withdrawal latencies of10 sec (n 4 in each case).
Lysolecithin treatment causes demyelination without overt
axonal damage or sensory loss
To determine the extent of demyelination as a result of lysoleci-
thin treatment, we examined demyelinated, sham, and naive pe-
Figure 2. Effects of lysolecithin treatment on the myelination state of the saphenous and sciatic nerve. a, Toluidine blue-stained resin sections (1m) from the ipsilateral ( i ) and contralateral
( ii ) saphenous nerves of lysolecithin-treated animals on day 13 after treatment, ipsilateral saphenous nerve of sham-treated animals on day 13 after treatment (iii), ipsilateral (iv ) and contralateral
( v) sciatic nerves of lysolecithin-treated animals on day 13 after treatment, and ipsilateral sciatic nerve of sham-treated animals (vi ) on day 13 after treatment were analyzed by light microscopy
(n 4 in each case). Contralateral nerves on day 13 after lysolecithin treatment and nerves ipsilateral to sham treatment all appeared to be morphologically normal with consistent levels of
myelination across the nerve. Scale bar, 10m. b, Quantification of the degree of myelination of A-fibers after lysolecithin treatment to the saphenous nerve was determined as a g-ratio from
electron microscope images of the ipsilateral and contralateral saphenous nerves of lysolecithin-treated ( i ) and sham animals ( ii ) on day 13 after, ipsilateral and contralateral sciatic nerve of
lysolecithin-treated ( iii ) and sham animals (iv) on day 13 after treatment (n 4 in each case). Results are shown as the mean g-ratio of each fiber as a function of the axon diameter (i–iv), and the
data are summarized as bar charts below (v). The data show a general decrease in myelin thickness, i.e., increased g-ratio after lysolecithin treatment but not after sham surgery. Statistical
significance (*p 0.05) between conditions was determined by Kruskal–Wallis one-way ANOVA on ranks with an all pair-wise multiple comparisons procedure (Dunn’s method).
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ripheral nerves by light and electron microscopy at the time of
peak behavioral change. A maximum of 40% of A-fibers in the
saphenous nerve was completely demyelinated 11–13 d after ly-
solecithin treatment, and many remaining myelinated fibers had
myelin of reduced thickness. This was observed by light micros-
copy (Fig. 2a) and calculated from the number of myelinated
fibers or formerly myelinated fibers present in each EM image
(representing 292m 2 of the nerve). Lysolecithin-treated saphe-
nous nerve (n 4) contained 4.9 0.9 myelinated axonal pro-
files per area sampled (155 profiles over 33 images analyzed), and
control nerve (n 4) contained 8.2 1.7 profiles per area sam-
pled (261 myelinated axonal profiles over 32 images analyzed).
After topical application of lysolecithin, a similar degree of demy-
elination was observed in the sciatic nerve as in the saphenous
nerve (Fig. 2a). The g-ratios were calculated for the remaining
myelinated A-fibers in each nerve after treatment with lysoleci-
thin. The g-ratio was significantly increased in the demyelinated
saphenous nerve from 0.61 0.01 in contralateral control nerves
to 0.76 0.01 in demyelinated nerves and similarly in the demy-
elinated sciatic nerve from 0.56  0.02 in contralateral control
nerves to 0.81 0.03 in demyelinated nerves (Fig. 2b), indicating
a general decrease in myelin thickness. There was no significant
difference in the level of myelination in sham-operated animals
compared with control naive animals.
Electron microscopy demonstrated that after lysolecithin
treatment unmyelinated C-fiber bundles appeared to be mor-
phologically normal, and fiber counts revealed no statistically
significant change in the number of unmyelinated C-fibers per
EM image of either saphenous or sciatic nerve (Fig. 3a,b, Table 1).
Furthermore, the total number of larger A-fiber axons that were
either myelinated or demyelinated was also unchanged in saphe-
nous or sciatic nerve after lysolecithin (Fig. 3a,b, Table 1). Hence,
there was no evidence that treatment with lysolecithin under the
conditions used in these experiments affects the integrity of
axons.
Lysolecithin treatment induces ectopic firing in saphenous
afferents in the absence of changes in conduction velocity or
peripheral thresholds
At 3 and 5 d after lysolecithin treatment, reflex testing showed no
detectable change in either mechanically or thermally evoked re-
sponses, indicating that a sensitized state had not yet developed.
Neither at this time nor at the time of peak behavioral change
(11–13 d after treatment) was there any significant difference
among normal, sham, and demyelinated afferent fibers in the
Figure 3. Effects of lysolecithin treatment on morphology of saphenous and sciatic nerve
fibers at the EM level. a, Electron microscopy images of either the lysolecithin-treated saphe-
nous ( i ) or sciatic ( iii ) nerves, compared with the equivalent sham-operated nerves [saphenous
( ii ) and sciatic (iv) nerves] on day 13 after treatment (n 4 in each case). Thirteen days after
lysolecithin treatment, ipsilateral nerves display complete demyelination in40% of A-fibers
with partial demyelination of many remaining myelinated fibers. The images demonstrate
marked lysolecithin-induced reduction in the myelination of A-fibers (arrow), whereas C-fibers
(arrowhead) remain intact (5000). Scale bar, 2m. b, i and ii show the mean number of C-
and A-fibers recorded per image area in different conditions. Unmyelinated axons were identi-
fied as small-diameter fibers devoid of any myelin sheath (which were present in bundles,
surrounded by Schwann cell cytoplasm) and were individually counted for all groups. A-fibers
(with or without lysolecithin treatment) were identified as the larger-diameter axons with
myelin sheaths or smaller-diameter thinly myelinated fibers or occasionally those with no my-
elin that were solitary. Data for both fiber types are presented as average numbers of fibers per
292 m 2 image SEM. A Kruskal-Wallis one-way ANOVA on ranks showed no statistically
significant differences between treatment groups.
Table 1. Effects of topical lysolecithin treatment on afferent fiber numbers
Nerve Treatment Side
Average number of axons
per 292 mm2 EM image
A-fibers C-fibers
Sciatic Lysolecithin Ipsi 6.8 1.5 45.1 9.0
Lysolecithin Contra 7.9 2.2 42.9 8.9
Sham Ipsi 6.7 3.3 39.3 7.3
Saphenous Lysolecithin Ipsi 10.1 0.5 60.1 2.0
Lysolecithin Contra 11.8 0.2 62.9 1.9
Sham Ipsi 9.7 0.3 57.3 1.3
EM images were analyzed to count profiles characteristic of C-fiber axons or A-fiber axons that were either still
myelinated or had been demyelinated to varying degrees. No differences were apparent in the number of A-fiber or
C-fiber axons between lysolecithin-treated and control animals. Ipsi, Ipsilateral; Contra, contralateral.
Table 2. Effects of topical lysolecithin treatment of the saphenous nerve on
afferent fiber characteristics
Treatment
Receptive
field
Spontaneous
activity
(imp/sec)
von Frey
filament
threshold
(mN/mm2)
Thermal
threshold
(oC)
Conduction
velocity
range
(msec1)
Naive Normal 0 8.41–16.70 48 1.4 –20.0
Sham (day 11–13) Normal 0 8.41–16.70 48 0.9 –18.2
Lysolecithin-treated
(day 3- 5) Normal 0 8.41–16.70 48 0.5–16.6
Lysolecithin-treated
(day 11–13) Normal 0 8.41–16.70 48 1.3–16.0
Electrophysiological recordings of afferent fiber unit activity and cutaneous responsiveness were performed on
animals 3–5 d (n4) and 11–13 d (n6) after lysolecithin treatment to the saphenous nerve, 11–13 d after sham
treatment (n 4), and on naive animals (n 4). The total numbers of afferent units recorded in each condition
were 21, 66, 25, and 49, respectively. Any sensitization of mechanical sensory receptors with high thresholds was
measured using calibrated von Frey filaments, and the presence of any sensitization of thermally responsive recep-
tors was measured with a calibrated radiant heat lamp. The conduction velocity range of afferent fiber units was
determined using the peripheral stimulus technique via bipolar electrodes. There was no difference in threshold for
unit firing in response to mechanical or thermal stimulation or conduction velocity range among any of the groups.
Afferent fiber units of the lysolecithin-treated nerves (11–13 d after treatment) displayed spontaneous activity.
imp/sec, Impulses per second.
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threshold for their firing response to von
Frey filaments or to thermal nociceptive
stimuli (Table 2). Thus there is no evi-
dence that changes in peripheral transduc-
tion mechanisms might be responsible for
the increased behavioral reflex sensitivity
that was observed (Table 2). The focal na-
ture of this demyelination together with
the integrity of the axons was reflected in
the normalrange of overall conduction ve-
locities compared with sham and control
nerves. The range included slow conduc-
tion velocities of 1 msec1 up to the
fastest in the range of 20 msec–1. Further-
more, the number of units recorded for each conduction velocity did
not differ significantly among the lysolecithin-treated, sham, and
naive nerves (Fig. 4a, Table 2). This provided further support for the
view that there had been no significant axon damage.
A common feature of lysolecithin-demyelinated nerves over a
range of 11–13 d after application, however, has been the pres-
ence of a spontaneous low-frequency discharge (2–3 impulses per
second), reminiscent of a similar discharge that we have observed in
the sciatic nerve of Prx-null mice (Gillespie et al., 2000) (Fig. 4b).
Expression of NF-200, peripherin, and the axonal damage
marker ATF3 in DRG is unaffected by lysolecithin treatment
To assess the integrity of the cell bodies 13 d after lysolecithin
treatment of the saphenous or sciatic nerve, we analyzed the ex-
pression of NF-200, which labels the larger-diameter, myelinated
DRG cell population (Lawson and Waddell, 1991; Michael et al.,
1999), and peripherin, a type III intermediate filament protein,
which is normally expressed selectively by unmyelinated sensory
neurons (Amaya et al., 2000). No significant difference was ob-
served in the number of either NF-200 or peripherin-positive
DRG neurons ipsilateral to lysolecithin compared with contralateral
or sham treatment of the sciatic or saphenous nerve (Table 3).
We also analyzed the expression of ATF3, a member of the
ATF/cAMP response element-binding protein (ATF/CREB)
family (Hai et al., 1999), which is induced in DRG neurons after
peripheral nerve injury and thus considered to be a nerve injury
marker, identifying axotomized neurons (Tsujino et al., 2000). As
a positive control, we analyzed the expression of ATF3 in the
DRG of mice, which were at the peak of neuropathic sensitization
after chronic constriction injury (CCI) to the sciatic nerve. In
CCI mice we found expression of ATF3 in 69 16% of ipsilateral
DRG neurons. Under control (sham) conditions we found a very
small number of ATF3-positive cells, all of which were also pos-
itive for NF-200. However, there was no significant increase in
the proportion of ATF3-immunopositive cells in the DRG ipsi-
lateral to lysolecithin treatment of the sciatic nerve as compared
with contralateral or sham-treated animals (Fig. 5a, Table 4).
Lysolecithin treatment causes a distinctive pattern of
neuropeptide expression in sensory neurons
After traumatic injury to the peripheral nerve, there are a number
of neurochemical and morphological changes, both in peripheral
nerve fibers and centrally in the spinal cord (Dray et al., 1994;
Hokfelt et al., 1994), that can contribute to the altered sensory
transmission associated with chronic pain states. Phenotypic
changes occur in many primary afferent DRG neurons, resulting
in the altered expression of neuropeptides including CGRP, ga-
Figure 4. Effects of lysolecithin treatment on electrophysiological properties of saphenous
afferents. a, Afferent fiber units from the lysolecithin-treated saphenous nerve of animals on
days 11–13 after treatment (n 6) displayed a range of conduction velocities that were not
significantly different from those of fibers from naive nerves (n 4). The range included slow
conduction velocities of1 msec 1 up to the fastest in the range of 20 msec –1. The number
of units recorded for each conduction velocity did not differ significantly among the lysolecithin-
treated (black column), naive (white column), and sham (gray column) nerves. b, Electrophys-
iological recordings of saphenous afferent fiber unit activity 11, 12, and 13 d after lysolecithin
treatment to the saphenous nerve (n 6), 11–13 d after sham treatment (n 4), and in naive
animals (n 4). Spontaneous activity in saphenous afferents was recorded with a frequency of
2–3 Hz. Examples of electrophysiological recordings of naive ( i), sham-treated (ii), and
lysolecithin-treated (iii) nerves are displayed.
Table 3. Immunohistochemical assessment of structural markers and the neuropeptide CGRP in DRG cells after
lysolecithin treatment
Nerve Treatment Side
Number of positive cells per DRG
NF-200 Peripherin CGRP
Sciatic Lysolecithin Ipsi 78.5 3.2 129.7 19.6 145.9 19.7
Lysolecithin Contra 77.3 2.2 119.7 4.6 154.5 9.1
Sham Ipsi 68.1 9.6 109.4 9.6 149.6 5.8
Sham Contra 73.4 2.7 103.9 1.9 129.9 12.9
Saphenous Lysolecithin Ipsi 67.1 6.2 120.4 11.6 152.8 8.7
Lysolecithin Contra 74.3 13.9 124.7 8.6 135.3 7.4
Sham Ipsi 69.9 9.7 119.5 9.1 139.6 5.8
Sham Contra 71.7 9.6 121.7 4.6 132.4 9.6
The expression of the neuronal structural markers peripherin and NF-200 and the peptide CGRP in DRG cells ipsilateral and contralateral to lysolecithin
treatment of the saphenous or sciatic nerve on day 13 after treatment and from sham animals (n 4 in each case). There was no difference in the number of
cells expressing either structural marker after treatment with lysolecithin as determined by a Kruskal–Wallis one-way ANOVA on ranks or paired Student’s t
test. Data are presented as average number of immunopositive cells per DRG SEM. Ipsi, Ipsilateral; Contra, contralateral.
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lanin, and NPY (Villar et al., 1991; Hokfelt et al., 1994). We
therefore investigated whether such changes occur in the
demyelination-induced pain state to compare the changes with
those occurring in other models of neuropathic pain in which
axonal damage is a major factor. CGRP is normally expressed by
approximately one-half of unmyelinated DRG neurons as well as
one-fifth of those with A myelinated neurons (Rosenfeld et al.,
1983; Gibson et al., 1984; McCarthy and Lawson, 1990; Hokfelt et
al., 1994) and is downregulated after peripheral nerve injury such
as axotomy and CCI (Noguchi et al., 1990; Dumoulin et al.,
1992). However, there was no significant difference in the num-
bers of ipsilateral versus contralateral DRG cells expressing im-
munoreactive CGRP after lysolecithin treatment or sham treat-
ment of one sciatic nerve or of one saphenous nerve (Table 3),
suggesting that lysolecithin treatment caused no extensive dam-
age to the axons of CGRP-expressing cells.
Further immunohistochemical investigations were restricted
to the sciatic model of lysolecithin-induced demyelination, be-
cause it is a larger nerve and would contribute a larger proportion
of cell bodies in relevant DRGs, thereby facilitating detection of
changes.
Galanin is normally expressed at very low levels in sensory and
sympathetic neurons. However, after peripheral nerve lesions, it
is strongly upregulated mainly in small and medium-sized neu-
rons (Hokfelt et al., 1987; Villar et al., 1989), especially those that
normally contain substance P and CGRP (Xu et al., 1990;
Doughty et al., 1991; Kashiba et al., 1992), the majority of which
are unmyelinated. However, we observed no significant galanin
immunoreactivity in DRG cells ipsilateral or contralateral to focal
demyelination of one sciatic nerve. As a positive control to test
the specificity of the antibody, we used DRG from mice at peak
neuropathic sensitization after sciatic CCI (Garry et al., 2003).
These sections showed a significant proportion of mainly small
diameter cells positive for galanin (ipsilateral 9.3  2.4 cells per
section; contralateral 0), verifying that the antibody could suc-
cessfully detect the presence of galanin when expressed after trau-
matic nerve injury and that there is, in contrast, no significant
upregulation after lysolecithin treatment.
NPY is not normally expressed in DRG cells (Lundberg et al.,
1983). However, the expression of NPY is strongly upregulated in
DRG neurons after axotomy (Wakisaka et al., 1991, 1992; Noguchi
et al., 1993; Kashiba et al., 1994), partial sciatic injury (Ma and Bisby,
1998), CCI of the sciatic nerve (Nahin et al., 1994; Munglani et al.,
1995), and streptozotocin-induced diabetic neuropathy (Ritten-
house et al., 1996). This upregulation occurs mainly in large primary
sensory neurons containing NF-200 (Kashiba et al., 1994; Marchand
et al., 1999). We also observed significant NPY immunoreactivity in
16% cells after demyelination of one sciatic nerve (185 NPY-
positive cells from 1164 NF-200-positive cells counted over 26 sec-
tions; n 4) as opposed to no detectable immunoreactivity in con-
tralateral or sham nerves (Table 4). All NPY-immunopositive cells
were also immunoreactive for NF-200, indicating that they were cells
with myelinated fibers (Fig. 5b).
Afferent expression of NaV1.8 and NaV1.3 is altered by
lysolecithin treatment
Normally, DRG neurons express a complex repertoire of sodium
channel transcripts (Waxman et al., 1999) distinguished by their
differential sensitivity to tetrodotoxin (TTX) (Black and Waxman,
1996). The TTX-resistant sodium channel NaV1.8 is expressed in
50% of small-diameter, unmyelinated DRG cells (Amaya et al.,
2000) and in20% of medium- to large-diameter, myelinated DRG
cells. Our results from the DRG of contralateral untreated nerve
confirm that result, showing expression of NaV1.8 in 1078 of the
2130 (51%) peripherin-immunopositive cells (C-fibers) and 500 of
the 2086 (24%) NF-200-immunopositive cells (myelinated fibers).
Likewise, in sham controls we saw Nav1.8 expressed in 51% of
peripherin-immunopositive cells ipsilaterally and 48% contralater-
ally and in 23% of NF-200-immunopositive cells ipsilaterally and
22% contralaterally. It has been shown previously that after axo-
tomy, CCI, or spinal nerve ligation, expression of Nav1.8 is down-
regulated in neurons in the DRG, a change that has been proposed to
contribute to the production of a neuropathic pain state (Dib-Hajj et
al., 1999; Waxman, 1999; Decosterd et al., 2002). In the L4, L5, and
L6 DRG taken from animals 13 d after lysolecithin treatment to the
sciatic nerve, there was a 34.14.2% reduction of Nav1.8 expression
in the ipsilateral DRG (62.4 3.4 NaV1.8-immunopositive cells per
section) versus the contralateral and sham DRG (with correspond-
ing values of 94.7  4.7 NaV1.8 and 95.7  6.0, respectively). To
address the question of whether these changes in sodium channel
expression were restricted to a subset of neurons, we performed dual
labeling experiments to reveal the colocalization of Nav1.8 with NF-
200/peripherin. The reduction in Nav1.8 expression appeared to be
restricted to NF-200-immunopositive cells, i.e., those presumed to
have formerly myelinated axons (Fig. 5c, Table 4). No change in the
number of cells coexpressing Nav1.8 and NF-200 was observed be-
tween the ipsilateral or contralateral DRG of sham control animals,
and we found no decrease in the proportion of peripherin-
immunoreactive cells expressing Nav1.8 after lysolecithin treatment
(Table 4).
The Nav1.3 channel is normally found in DRG only during
development, and consistent with this we could not detect ex-
pression of this channel in the DRG before treatment (Fig. 5d,
Table 4). However, expression of this channel has been reported
to increase in sensory neurons after axotomy (Black et al., 1999),
CCI, and spinal nerve ligation (Kim et al., 2001). After
lysolecithin-induced demyelination of the sciatic nerve, we found
a significant increase in the number of NF-200-immunoreactive
cells per ipsilateral DRG that now expressed Nav1.3 (18.5 
2.4%) (Fig. 5d, Table 4). No Nav1.3 positive cells were also im-
munopositive for peripherin, showing that expression of the
channel was not increased in C-fibers, and no Nav1.3 immuno-
reactivity was detected in contralateral or sham tissue.
Lysolecithin treatment causes NMDA receptor-dependent
central sensitization that can be reversed by cannabinoids
Sensitization of cells in the dorsal horn of the spinal cord is a key
change in other neuropathic pain states that is thought to involve
activation of the NMDA receptor (Wilcox, 1991; Codderre and
Melzack, 1992; Chaplan et al., 1997). We found that spinal
NMDA receptors also play a role in the mechanical allodynia seen
in animals with focal demyelination of the saphenous nerve, be-
cause behavioral sensitization was reversed after spinal adminis-
tration of the selective NMDA receptor antagonist (R)-CPP (Leh-
mann et al., 1987) (Fig. 6a). This parallels observations that we
made previously in a demyelination model based on the periaxin-
null mouse (Gillespie et al., 2000). Similarly, the reduction in
thermal nociceptive response latency ipsilateral to lysolecithin
treatment was reversed by (R)-CPP (Fig. 6e). There was no effect
of (R)-CPP on thermal or mechanical responses contralateral to
demyelination. Equivalent injections of the saline vehicle had no
effect on mechanical or thermal reflex responses either ipsilateral
or contralateral to lysolecithin (data not shown; n 4).
Because neuropathic pain states often show a relative insensitivity
to spinal opioid analgesia compared with acute or peripheral inflam-
matory pain states (Arner and Meyerson, 1988; Fleetwood-Walker
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et al., 1988; Yaksh and Harty, 1988), we assessed the effect of
the potent and selective -opioid receptor agonist DAMGO in
the lysolecithin model. Spinal -opioid receptors exert pow-
erful analgesic effects in inflammatory models of chronic pain
(Malmberg and Yaksh, 1993; Chaplan et al., 1997). At the highest
dose of intrathecal DAMGO that could be administered before overt
psychomotor incoordination was seen (10
pmol/10 l), there was no specific re-
versal of the mechanical allodynia or
thermal hyperalgesia seen ipsilateral to
lysolecithin treatment (data not shown;
n  4). The same intrathecal dose of
DAMGO produces significant analgesia
in tail pressure and thermal paw with-
drawal tests in mice (Sakurada et al.,
1999, 2001).
An alternative spinal modulatory sys-
tem that can exert selective antinociceptive
effects in both neuropathic and inflamma-
tory hyperalgesia is the endogenous can-
nabinoid system (Herzberg et al., 1997; Ri-
chardson et al., 1998a; Fox et al., 2001).
This is of particular interest because there
is evidence that cannabinoids may exert
analgesic and additional beneficial effects
in demyelinating diseases such as multiple
sclerosis (Consroe et al., 1997; Williamson
and Evans, 2000; Robson, 2001). In this
animal model of peripheral nerve demyeli-
nation, spinal administration of the can-
nabinoid receptor agonist WIN 55,212–2
attenuated the sensitization [that is the re-
duction in mechanical nociceptive thresh-
olds (Fig. 6b) and thermal reflex latencies
(Fig. 6f)] that was displayed ipsilateral to
lysolecithin. In both cases, changes were
limited to the lysolecithin-treated side and
were statistically significant up to 1 hr
after injection. The CB1 receptor in partic-
ular is implicated, because spinal adminis-
tration of the selective CB1 receptor antag-
onist AM 251 reversed the effects of WIN
55,212–2 on mechanical sensitization (Fig.
6c) and thermal sensitization (Fig. 6g).
However, when administered alone, AM
251 had no significant effect, indicating
that endogenous spinal CB1 receptors
had not become tonically activated as
a result of the lysolecithin treatment
(Fig. 6d,h).
Discussion
Abnormal sensory phenomena including
spontaneous pain, hyperalgesia, and allo-
dynia are associated with human periph-
eral demyelinating neuropathies such as
types of CMT and GBS. In CMT, although
sensory deficits are usually less severe than
motor problems, pain is a problem in
many sufferers and is a clear aspect of the
clinical picture in CMT4F (Carter et al.,
1998; Boerkoel et al., 2001; Guilbot et al.,
2001; Takashima et al., 2002). Similarly,
GBS or acute inflammatory polyneurop-
athy may involve pain in 54 – 84% of cases (Asbury, 1990; Mou-
lin, 1998). Because the mechanisms underlying neuropathic pain
in demyelinating disease are poorly understood (Rasminsky,
1981), we developed and characterized an animal model of focal
peripheral nerve demyelination.
Figure 5. Immunohistochemical colocalization of neuronal subtype markers with ATF3, NPY, and the sodium channel subtypes
Nav1.8 and Nav1.3 in DRG cells after lysolecithin treatment of the sciatic nerve. a, Expression of ATF3 in ipsilateral and contralateral
DRG sections from lysolecithin-treated animals on day 13 after treatment (n 4). There was no significant increase in expression
of ATF3 from that seen in control DRG after lysolecithin treatment or sham treatment. The statistical significance (*p 0.05) of
any difference was determined by a Kruskal–Wallis one-way ANOVA on ranks with all pair-wise multiple comparison procedures
(Dunn’s method). Images show nuclei of ATF3-immunopositive cells labeled with FITC (green) and NF-200-immunopositive cells
labeled with TRITC (red), in ipsilateral ( i) and contralateral (ii) DRG from lysolecithin-treated animals and ipsilateral DRG (iii) from
CCI animals. Scale bar, 20 m. b, Expression of the neuropeptide NPY in ipsilateral and contralateral DRG sections from
lysolecithin-treated animals at 13 d after treatment (n 4). Images show NF-200-immunopositive cells labeled with TRITC (red)
and NF-200/NPY-colocalized, immunopositive cells labeled with FITC (green) in DRG ipsilateral to lysolecithin treatment ( i) as
opposed to no positive cells in DRG contralateral to lysolecithin treatment (ii). Scale bar, 20m. c, The expression of the Nav1.8
channel in ipsilateral and contralateral DRG sections from lysolecithin-treated animals on day 13 after treatment (n 4). After
lysolecithin treatment of the sciatic nerve, there was a decrease in the number of cells expressing Nav1.8 in ipsilateral DRG
compared with contralateral DRG, all of which were immunopositive for NF-200. There was no significant decrease in expression
after sham treatment. The statistical significance (*p 0.05) of any difference was determined by a Kruskal–Wallis one-way
ANOVA on ranks with all pair-wise multiple comparison procedures (Dunn’s method). Images show Nav1.8-immunopositive cells
labeled with FITC (green) and NF-200-immunopositive cells labeled with TRITC (red), with coexpression appearing yellow in
ipsilateral ( i) and contralateral (ii) DRG from lysolecithin-treated animals. Scale bar, 20m. d, Expression of the Nav1.3 channel
in ipsilateral and contralateral DRG sections from lysolecithin-treated animals 13 d after treatment and sham-treated animals on
the same day after treatment (n 4 in each case). Images show NF-200-immunopositive cells labeled with TRITC (red) and
Nav1.3-immunopositive cells labeled with FITC (green) with coexpression appearing yellow in DRG ipsilateral to lysolecithin
treatment ( i) as opposed to no positive cells in DRG contralateral to lysolecithin treatment (ii). Scale bar, 20m.
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Morphology of the demyelinated nerve
To understand the mechanisms underly-
ing demyelination-induced neuropathic
pain, it is important to establish whether
axonopathic changes may contribute. The
protocol used here results in demyelina-
tion of rapid onset confined to the imme-
diate vicinity of the site of injection, caus-
ing little damage to the Schwann cell
cytoplasm (Love et al., 1986) or the axon
(Figs. 2, 3). However, because small-
diameter fibers may be damaged by lyso-
lecithin injection into the nerve (Mitchell
and Caren, 1982), we applied lysolecithin
topically to the saphenous or sciatic nerve,
producing a focal demyelination without
detectable axon damage or loss as assessed
by light and electron microscopy. Corre-
spondingly, in immunohistochemical
studies we found neither loss of neuronal
somata in the DRG, which were positive for NF-200 or periph-
erin, nor increased expression of the neuronal injury marker
ATF3. This model of peripheral nerve demyelination appears to
involve neither axonopathy nor cell loss and in that sense is less
severe than models of neuropathic pain such as axotomy, CCI,
and spinal nerve ligation (SNL), which involve axonal injury.
Demyelination-induced allodynia and hyperalgesia: the role
of functional changes in peripheral nerve
Damage to sensory nerves as a result of human peripheral demy-
elinating disease has been linked to pain and heightened sensitiv-
ity to touch (Pentland and Donald, 1994; Devor and Seltzer,
1999). After lysolecithin treatment of either the mixed sciatic
nerve or the sensory saphenous nerve, we have demonstrated, for
the first time, the development of mechanical allodynia and ther-
mal hyperalgesia. Peripheral sensitization may contribute to neu-
ropathic pain behavior in other models (Koltzenburg, 1998;
Woolf and Costigan, 1999), but in the demyelination model we
could find no significant changes in the cutaneous threshold for
action potential generation by mechanical or thermal nociceptive
stimuli in either A- or C-fibers. Some forms of mechanical allo-
dynia are considered to be mediated by myelinated A-fibers pro-
viding inputs that are inappropriately processed by sensitized
dorsal horn neurons (Woolf, 1997; Koltzenburg, 1998). Indeed,
in the conditions that occur after section of peripheral or spinal
nerves (for example, with phenotypic changes in DRG cells),
spontaneous, ectopic activity in A, but not C afferents may play a
role in the induction of neuropathic pain behaviors (C. N. Liu et
al., 2000; X. Liu et al., 2000). Such activity may be important in
the development of neuropathic pain here because repetitive ec-
topic firing may underlie abnormal sensation in diseases involv-
ing segmental demyelination, particularly where axonopathic
changes are lacking (Rasminsky, 1981). The presence of low-
frequency spontaneous discharge in demyelinated saphenous
nerve corresponded to times of peak behavioral reflex sensitivity
and was similar to observations in the Prx-null mouse (Gillespie
et al., 2000). Because inflammatory neuritis can lead to a sensi-
tized neuropathic pain state (Eliav et al., 1999), the possibility
should be considered that a neuroimmune response could con-
tribute to generating the allodynia and hyperalgesia observed
here. However, in the Prx-null mouse, an alternative model of
demyelination-induced neuropathic pain, minimal evidence
could be found for macrophage infiltration of the degenerating
structures (Gillespie et al., 2000), suggesting that demyelination
per se is a critical factor in generating the neuropathic pain state.
Phenotypic changes in the DRG
After peripheral nerve lesions, changes in the expression of pep-
tides occur in primary sensory neurons that may contribute to
mediating central sensitization (Hokfelt et al., 1994). We assessed
whether changes in the lysolecithin model are similar to those in
other models of neuropathic pain, such as the downregulation of
CGRP and the upregulation of galanin and NPY. Because this
model appears to cause morphological and functional changes
only in myelinated afferents, we asked whether changes in pep-
tide expression are similarly restricted. Alterations in CGRP and
galanin expression (generally in small-diameter afferents) have
been implicated in the development of neuropathic pain (Hokfelt
et al., 1987; Villar et al., 1989; Dumoulin et al., 1992; Kerr et al.,
2000; Wynick et al., 2001), but we saw no change in these peptides
after peripheral nerve demyelination.
We did find, however, upregulated expression of NPY, re-
stricted to large NF-200-positive cells ipsilateral to focal demyeli-
nation. This parallels changes seen in other models of neuro-
pathic pain. Notably, the upregulation of NPY occurred without
any alteration in the expression of ATF3, indicating that direct
neuronal injury was not responsible for the effect. After axotomy
(Waxman et al., 1994), CCI (Dib-Hajj et al., 1999), and SNL (Kim
et al., 2001), changes are seen in the expression of sodium channel
isoforms, leading to functional changes in afferent sodium cur-
rents. For example, Nav1.8 [expressed preferentially in small- and
medium-diameter DRG and implicated in pathological pain
states (Akopian et al., 1996; Sangameswaran et al., 1996; Novak-
ovic et al., 1998)], is downregulated (Dib-Hajj et al., 1996; Wax-
man, 1999), whereas Nav1.3 (normally found only in the DRG
during development) is upregulated (Waxman et al., 1994; Wax-
man, 1999). We found a similar decrease in the expression of
Nav1.8 channels in the DRG after focal demyelination that was
restricted to formerly myelinated cells. In contrast, Nav1.3 was
upregulated in corresponding cells. This further supports the
specificity of A-fiber changes in evoking neuropathic pain after
demyelination. Changes in channel type and distribution could
contribute to hyperexcitability and ectopic pacemaker activity
(Matzner and Devor, 1992, 1994; Devor et al., 1994; Cummins
and Waxman, 1997; Omana-Zapata et al., 1997; Waxman, 1999).
Na channel-blocking agents may be effective analgesics not
only in nerve injury-induced neuropathic pain (Chabal et al.,
Table 4. Immunohistochemical assessment of ATF3, the neuropeptide NPY, and the sodium channel subtypes
Nav1.8 and Nav1.3 in sciatic nerve DRG cells after lysolecithin treatment
Treatment Side
Positive cells as a proportion of NF-200/peripherin-positive cells (%)
ATF3/
NF-200
NPY/
NF-200
Nav1.8/
NF-200
Nav1.8/
peripherin
Nav1.3/
NF-200
Lysolecithin Ipsi 7.3 3.2 13.1 2.2* 15.7 1.6* 54.8 3.7 18.5 2.4*
Lysolecithin Contra 6.1 1.4 0 24.0 2.6 50.6 6.3 0
Sham Ipsi 8.2 3.4 0 24.0 2.9 51 1.4 0
Sham Contra 5.1 3.2 0 22.5 2.7 48.1 2.4 0
The expression of NPY, ATF3, and the sodium channels Nav1.8 and Nav1.3 in DRG cells ipsilateral (Ipsi) and contralateral (Contra) to lysolecithin treatment of
the sciatic nerve are shown for day 13 after treatment (n 4) and from sham animals (n 4). There was no significant increase in expression of ATF3 from
that seen in contralateral DRG after lysolecithin treatment or sham treatment. All ATF3-expressing cells were NF-200 immunopositive, and none were
peripherin immunopositive. After lysolecithin treatment of the sciatic nerve there was a significant increase in the number of cells expressing NPY, which were
all positive for NF-200 and none of which were immunopositive for peripherin. There was no detectable expression of NPY in the DRG contralateral to
lysolecithin treatment or in DRG cells from sham-treated animals. Ipsilateral to lysolecithin treatment, there was a decrease in the number of DRG cells
expressing Nav1.8 together with NF-200 compared with contralateral DRG or sham controls. In contrast, there was no significant decrease in the proportion
of cells coexpressing Nav1.8 and peripherin. Expression of the Nav1.3 channel became detectable in a subpopulation of NF-200- immunopositive cells after
lysolecithin treatment, whereas there was no detectable expression in the contralateral DRG or in DRG from sham-treated animals. No coexpression of Nav1.3
with peripherin was detected. The statistical significance (* p 0.05) of any difference between each group was determined by a Kruskal–Wallis one-way
ANOVA on ranks with all pair-wise multiple comparison procedures (Dunn’s method). Data are presented as the mean SEM percentage of total NF-200-
positive cells that were positive for the relevant marker.
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Figure 6. Effects of intrathecal administration of NMDA and cannabinoid receptor-targeting agents on sensitized behavioral reflex responses after lysolecithin treatment. Paw withdrawal
thresholds in response to cutaneous mechanical stimulation with von Frey filaments (a–d) and paw withdrawal latencies in response to cutaneous noxious thermal stimulation (e–h) were measured
in animals at peak behavioral reflex sensitivity after topical application of lysolecithin to one saphenous nerve. Ipsilateral () and contralateral () values are displayed before and after intrathecal
administration of each pharmacological agent as paw withdrawal threshold in milliNewtons per millimeter squared (mN/mm 2) for mechanical stimulation or paw withdrawal latency (seconds) for
thermal stimulation. For all measurements, each value is the mean SEM, and statistical significance (*p 0.05) of any differences between postinjection threshold values and preinjection
baseline values was determined by a one-way repeated measures ANOVA with Dunnet’s post hoc analysis. a, e, The NMDA receptor antagonist ( R)-CPP (100 pmol) reversed the behavioral reflex
sensitivity to mechanical stimulation ( a) and thermal stimulation ( e) in lysolecithin-treated animals for up to 65–70 min after intrathecal application (n 8). b, f, The mixed CB1 /CB2 cannabinoid
receptor agonist WIN 55,212–2 (60 pmol) significantly reversed the behavioral reflex sensitivity to mechanical stimulation ( b) and thermal stimulation ( f) in lysolecithin-treated animals (n 7)
for up to 55– 60 min after intrathecal application. c, g, When injected in combination, WIN 55,212–2 and AM 251 produced no significant effect on the behavioral reflex sensitivity to mechanical
stimulation (c) and thermal stimulation ( g) in lysolecithin-treated animals (n 8). d, h, The CB1 receptor antagonist AM 251 (100 pmol) resulted in no change in the behavioral reflex sensitivity to
mechanical stimulation ( d) and thermal stimulation ( h) in lysolecithin-treated animals (n 7).
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1992; Devor et al., 1992; Omana-Zapata et al., 1997; Rizzo, 1997),
but also in demyelination-induced pain.
Central changes after afferent demyelination and central
modulation of sensitization
Afferent hyperexcitability and ectopic firing after lysolecithin
treatment provide a basis for the ongoing input that brings about
central sensitization. Because a spinal NMDA antagonist reverses
sensitization in lysolecithin-treated mice, central changes play a
critical role in the phenotype. NMDA receptors are similarly im-
portant in the mechanical allodynia and thermal hyperalgesia of
other chronic pain models (Dickenson and Sullivan, 1987; Mao
et al., 1993; Bennett, 1994; Chaplan et al., 1997; Woolf and Costi-
gan, 1999). The relative insensitivity of neuropathic pain models
to spinally administered opioid analgesics (Arner and Meyerson,
1988; Yaksh and Harty, 1988; Lee et al., 1995) also corresponds to
our findings in the lysolecithin demyelination model.
Cannabinoid receptor drugs may represent an alternative
strategy for the relief of chronic pain. Spinal cannabinoids can
effectively modulate nociception (Herzberg et al., 1997; Richard-
son et al., 1998a; Martin et al., 1999; Bridges et al., 2001; Fox et al.,
2001; Kelly and Chaplan, 2001), and the majority of these anal-
gesic effects appear to be CB1 receptor-mediated (Richardson et
al., 1998b). In line with experiments on nerve-injury pain (Herz-
berg et al., 1997; Bridges et al., 2001; Fox et al., 2001), we found
that intrathecal administration of the mixed CB receptor agonist
WIN 55,212–2 attenuated mechanical allodynia and thermal hy-
peralgesia in lysolecithin-treated mice. This effect was reversed by
the CB1 antagonist AM 251, although AM 251 had little effect
alone. It is possible that additional, noncannabinoid side effects
of the compounds may occur in the immediate vicinity of the
intrathecal injections where the local concentrations are higher,
but the most likely explanation is that the WIN 55,212–2-
induced, AM-251-reversed analgesia is mediated by CB1 recep-
tors. The efficacy of cannabinoids in the treatment of neuro-
pathic pain may be linked to their actions on myelinated A-fibers.
Under normal conditions, spinal cannabinoid receptors may
predominantly regulate C-fiber input to the spinal cord, but after
nerve injury these effects may be lost, whereas inhibitory influ-
ences on A-fiber inputs are retained (Chapman, 2001). This
might result in cannabinoid agonists causing a reduction of me-
chanical allodynia, with more limited effect on thermal hyperal-
gesia, consistent with evidence from a number of studies (Herz-
berg et al., 1997; Bridges et al., 2001; Fox et al., 2001). In the
present model, in which C-fiber primary afferents appear to be
unaffected, both mechanical (A-fiber) and thermal (C-fiber) in-
puts should be targeted effectively by cannabinoids, as observed
experimentally. These findings point further to the potential use
of cannabinoids as therapeutic agents in human demyelinating
neuropathies.
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